Dr. Falk PharmaFalk Foundation
  • About us
    About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Indications
    Indications
    • Crohn’s Disease
    • Eosinophilic Oesophagitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our products
  • News
  • Education centre
Search
Please choose your country
  • Global (English)
  • Australia
  • België (Vlaams)
  • Belgique (Français)
  • Deutschland
  • España
  • France
  • Ireland
  • Italia
  • Luxembourg (Français)
  • Nederland
  • Österreich
  • Portugal
  • Россия
  • Schweiz (Deutsch)
  • Suisse (Français)
  • United Kingdom
more info

Contact:
Phone:1800 DRFALK (1800 373 255) Email: admin@drfalkpharma.com.au

  • About us
  • Search
  • Contact us
  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
HCP Portal
  • About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Indications
    • Crohn’s Disease
    • Eosinophilic Oesophagitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our products
  • News
  • Education centre
  • About us
  • Search
  • Contact us
  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
Contact:
Phone:
1800 DRFALK (1800 373 255)
Email:
admin@drfalkpharma.com.au
  • Homepage
  • Search

Search results

53 results

  • Resources
    Budenofalk Foam
  • Supplier Code of Conduct
    Supplier Code of Conduct Homepage About us Corporate Sustainability Supplier Code of Conduct Supplier Code of Conduct Company Policy Preamble Dr. Falk Pharma endeavors to live up to its responsibility…
  • Corporate Sustainability
    Corporate Sustainability Homepage About us Corporate Sustainability Sustainability at Falk In 2023 we embarked on a strategy process over the course of several months in which we developed a…
  • Policy Statement
    Policy Statement Homepage About us Corporate Sustainability Policy Statement Policy Statement for Dr. Falk Pharma GmbH and its Affiliated Companies Preface As a family-run and family-owned company, we…
  • Ulcerative colitis
    Ulcerative colitis Homepage Indications Ulcerative colitis Ulcerative colitis Ulcerative colitis is one of the disorders known as inflammatory bowel disease (IBD). Other disorders within this group of…
  • Crohn’s Disease
    Crohn’s Disease Homepage Indications Crohn’s Disease Crohn’s Disease Crohn’s disease belongs to the group of disorders known as inflammatory bowel disease. Definition A diagnosis of “Crohn’s disease”…
  • Primary Biliary Cholangitis
    Primary Biliary Cholangitis Homepage Indications Primary Biliary Cholangitis Primary Biliary Cholangitis Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the small bile ducts in…
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • »
Falk Foundation

Discover the range of continuing education opportunities for physicians and pharmacists provided by the Falk Foundation e.V.

Dr. Falk Pharma Australia

Dr. Falk Pharma is the expert in digestive and metabolic medicine. As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. 

  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
  • Crohn’s Disease
  • Eosinophilic Oesophagitis
  • Primary Biliary Cholangitis
  • Ulcerative colitis
© 2026 Dr. Falk Pharma Australia Pty Ltd
  • Terms & conditions of use
Notice

This website is an international information resource intended for healthcare professionals outside the United States (US) and United Kingdom (UK).

I am a health care professional outside the US and UK.

Accept
Notice
I confirm I am a UK or Irish resident and have been prescribed either Budenofalk®, Jorveza®, Salofalk® or Ursofalk®
Accept

You are leaving the website of Dr. Falk Pharma in Australia.

We are not liable for the accuracy of any content published on third party websites – such as the one you are about to be forwarded to.